Drug
Trastuzumab vedotin clinical trials
Also written MRG002.
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
10 studies that test it; most in 2021 (6)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2021 | 6 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Shanghai Miracogen Inc. (10)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses trastuzumab vedotin is read from its arms, and is right about nine times in ten.
Testing it · 10
- A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) CancerActive, not recruitingPhase 1/2Shanghai Miracogen Inc.NCT04492488Written as MRG002
- A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast CancerStatus unknownPhase 2/3Shanghai Miracogen Inc.NCT04924699Written as MRG002
- A Study of MRG002 in Treatment of Advanced HER-2 Positive Breast Cancer PatientsStatus unknownPhase 2Shanghai Miracogen Inc.NCT05263869Written as MRG002
- A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.Status unknownPhase 1/2Shanghai Miracogen Inc.NCT05338957Written as MRG002+HX008
- A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)Status unknownPhase 2Shanghai Miracogen Inc.NCT04742153Written as MRG002
- A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.Status unknownPhase 2Shanghai Miracogen Inc.NCT05141747Written as MRG002
- A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium CancerStatus unknownPhase 2Shanghai Miracogen Inc.NCT04839510Written as MRG002
- A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract CancerStatus unknownPhase 2Shanghai Miracogen Inc.NCT04837508Written as MRG002
- A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid TumorsStatus unknownPhase 1Shanghai Miracogen Inc.NCT04941339Written as MRG002
- A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).Status unknownPhase 2Shanghai Miracogen Inc.NCT05141786Written as MRG002
As the comparator · 1 — what is tested is compared with trastuzumab vedotin
Codes
What other systems call trastuzumab vedotin · ClinicalTrials.gg INT018331
- UNII (FDA) W95G28K44STRASTUZUMAB VEDOTINOne source FDA
- NCI Thesaurus C174205Trastuzumab VedotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | W95G28K44S | TRASTUZUMAB VEDOTIN | One source FDA |
| NCI Thesaurus | C174205 | Trastuzumab Vedotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.